- Home
- INTR vs CERT Comparison
INTR vs CERT Comparison
Compare INTR & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTR
- CERT
- Stock Information
- Founded
- INTR 1994
- CERT 2008
- Country
- INTR Brazil
- CERT United States
- Employees
- INTR N/A
- CERT N/A
- Industry
- INTR
- CERT Retail: Computer Software & Peripheral Equipment
- Sector
- INTR
- CERT Technology
- Exchange
- INTR Nasdaq
- CERT Nasdaq
- Market Cap
- INTR 2.5B
- CERT 2.3B
- IPO Year
- INTR N/A
- CERT 2020
- Fundamental
- Price
- INTR $7.14
- CERT $11.98
- Analyst Decision
- INTR Buy
- CERT Buy
- Analyst Count
- INTR 4
- CERT 6
- Target Price
- INTR $6.48
- CERT $15.60
- AVG Volume (30 Days)
- INTR 2.3M
- CERT 2.8M
- Earning Date
- INTR 05-16-2025
- CERT 05-05-2025
- Dividend Yield
- INTR 1.13%
- CERT N/A
- EPS Growth
- INTR 176.00
- CERT N/A
- EPS
- INTR 0.33
- CERT N/A
- Revenue
- INTR $743,862,312.00
- CERT $394,498,000.00
- Revenue This Year
- INTR $84.15
- CERT $11.41
- Revenue Next Year
- INTR $15.63
- CERT $8.78
- P/E Ratio
- INTR $21.24
- CERT N/A
- Revenue Growth
- INTR 43.28
- CERT 9.37
- 52 Week Low
- INTR $3.88
- CERT $8.64
- 52 Week High
- INTR $7.84
- CERT $17.94
- Technical
- Relative Strength Index (RSI)
- INTR 74.24
- CERT 45.14
- Support Level
- INTR $6.34
- CERT $11.22
- Resistance Level
- INTR $7.20
- CERT $12.30
- Average True Range (ATR)
- INTR 0.23
- CERT 0.68
- MACD
- INTR 0.05
- CERT -0.32
- Stochastic Oscillator
- INTR 89.24
- CERT 18.37
About INTR Inter & Co. Inc.
Inter & Co Inc operates as a digital bank. The company's segment includes Banking & Spending; Investments; Insurance Brokerage; and Inter Shop & Commerce Plus. It generates maximum revenue from the Banking & Spending.
About CERT Certara Inc.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.